Ivonescimab plus chemotherapy in non–small cell lung cancer with EGFR variant: a randomized clinical trial
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-05-19 15:44:49 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
W Fang, Y Zhao, Y Luo, R Yang, Y Huang, Z He…
Jama, 2024
jamanetwork.com
Importance For patients with non–small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited. Objective To compare the efficacy of ivonescimab plus chemotherapy with chemotherapy alone for patients with relapsed advanced or metastatic non–small cell lung cancer with the epidermal growth factor receptor (EGFR) variant. Design, Setting, and Participants Double-blind, placebo-controlled …
